Bio Briefs
Posted By
Recent Posts on This Topic | See All >
-
Jan 03, 2012 Nature speaks with Keim about H5N1 studies -
-
-
Jun 20, 2011 Promising skin-cancer drug nears approval
Share on Twitter
Share on Facebook
Email to a friend
Print Article
Precision Antibody to develop monoclonal antibodies for NCI
[Source: GenomeWeb News] – Precision Antibody said today that it will develop monoclonal antibodies for 20 cancer-related target proteins for a National Cancer Institute program, under an agreement with NCI contractor SAIC-Frederick.
The company will create the standardized, renewable antibodies for the NCI's Clinical Proteomic Technologies for Cancer (CPTC) project, which is focused on increasing the number of monoclonal antibody reagents that are available for clinical cancer proteomics research.
The CPTC is a five-year, $104 million effort to develop new proteomics tools and technologies to accelerate discovery and clinical research, Columbia, Md.-based Precision Antibody said in a statement.
For more information: Precision Antibody to Develop Monoclonal Antibodies for NCI
Quick Links
- NEW: About the Arizona Center for Civic Leadership
- Arizona Biosciences News
- Arizona BioMap
- Roadmap Progress Updates
- Reports & Multimedia
- Timeline: Arizona's Bio Growth
- Arizona Bio Orgs on Twitter
- Arizona BioBasics
- The Biozona Brand
- Newsletter Signup
Download a new brochure from the Flinn Foundation outlining the 2011 progress on Arizona's Bioscienced Roadmap: a record high in bioscience jobs, plus gains in firms and venture-capital funding. Numerous achievements during the year advanced the core strategies of the Roadmap.
Also, read the full Performance Assessment describing in detail Arizona's 2011 progress on key Roadmap metrics.
